Association of monocyte count on admission with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

Kardiologia Polska

Volumn 74, Issue 10, 2016, Pages 1160-1166

  Wang, Zuoyan ^a   Ren, Lihui ^a   Liu, Na ^a   Lei, Licheng ^a   Ye, Huiming ^a   Peng, Jianjun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Acute myocardial infarction; Monocyte count; No reflow phenomenon; Primary percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; CREATININE; HEMOGLOBIN; HEPARIN; TIROFIBAN;

ADULT; AGE DISTRIBUTION; AGED; ANGIOGRAPHY DEVICE; ARTICLE; BLOOD CELL COUNT; BLOOD CLOT LYSIS; CELL COUNT; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; INTRACORONARY DRUG ADMINISTRATION; LEUKOCYTE COUNT; LOADING DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOCYTE; NEUTROPHIL COUNT; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; SEX DIFFERENCE; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; VERY ELDERLY; BLOOD; DIAGNOSTIC IMAGING; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; ST ELEVATION MYOCARDIAL INFARCTION;

EID: 84991728659     PISSN: 00229032     EISSN: 18974279     Source Type: Journal    
DOI: 10.5603/KP.a2016.0065     Document Type: Article

References (28)

1. Grines CL, Browne KF, Marco J et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. the primary angioplasty in myocardial infarction study group. N Engl J Med, 1993; 328: 673-679. doi: 10.1056/NEJM199303113281001.
2. Lee CH, Tse HF. Microvascular obstruction after percutaneous coronary intervention. Catheter Cardiovasc Interv, 2010; 75: 369-377. doi: 10.1002/ccd.22234.
3. Zhang R, Brennan ML, Fu X et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA, 2001; 286: 2136-2142. doi: 10.1001/jama.286.17.2136.
4. Maekawa Y, Anzai T, Yoshikawa T et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol, 2002; 39: 241-246. doi: 10.1016/S0735- 1097(01)01721-1.
5. Charron T, Jaffe R, Segev A et al. Effects of distal embolisation on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow. Thromb Res, 2010; 126: 50-55. doi: 10.1016/j.thromres.2010.03.012.
6. Gibson CM, de Lemos JA, Murphy SA et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation, 2001; 103: 2550-2554. doi: 10.1161/01.CIR.103.21.2550.
7. Kirma C, Izgi A, Dundar C et al. Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center. Circ J, 2008; 72: 716-721. doi: 10.1253/circj.72.716.
8. Wang JW, Zhou ZQ, Chen YD et al. A risk score for no reflow in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Clin Cardiol, 2015; 38: 208-215. doi: 10.1002/clc.22376.
9. Morishima I, Sone T, Okumura K et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol, 2000; 36: 1202-1209. doi: 10.1016/S0735-1097(00)00865-2.
10. Tarantini G, Cacciavillani L, Corbetti F et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol, 2005; 46: 1229-1235. doi: 10.1016/j.jacc.2005.06.054.
11. van der Laan AM, Hirsch A, Robbers LF et al. A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST segment elevation myocardial infarction: monocytes and myocardial infarction. Am Heart J, 2012; 163: 57-65. doi: 10.1016/j.ahj.2011.09.002.
12. Maekawa Y, Anzai T, Yoshikawa T et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol, 2002; 39: 241-246. doi: 10.1016/S0735-1097(01)01721-1.
13. Wang J, Zhang S, Jin Y et al. Elevated levels of platelet-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome. Int J Cardiol, 2007; 115: 361-365. doi: 10.1016/j.ijcard.2006.03.019.
14. Zhang SZ, Jin YP, Qin GM et al. Association of platelet-monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-ST elevation acute coronary syndromes. Clin Cardiol, 2007; 30: 26-31. doi: 10.1002/clc.2.
15. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J, 1994; 8: 504-512. doi: 0892- 6638/94/0008-0504/$01.50.
16. Aukrust P, Berge RK, Ueland T et al. Interaction between chemokines and oxidative stress: Possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol, 2001; 37: 485-491. doi: 10.1016/S0735-1097(00)01110-4.
17. Nishiyama K, Ogawa H, Yasue H et al. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J, 1998; 62: 710-712. doi: 10.1253/jcj.62.710.
18. Bonderman D, Teml A, Jakowitsch J et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood, 2002; 99: 2794-2800. doi: 10.1182/blood. V99.8.2794.
19. Schwartz BG, Kloner RA. Coronary no reflow. J Mol Cell Cardiol, 2010; 52: 873-882. doi: 10.1016/j.yjmcc.2011.06.009.
20. Funayama H, Ishikawa SE, Sugawara Y et al. Myeloperoxidase may contribute to the no-reflow phenomenon in patients with acute myocardial infarction. Int J Cardiol, 2010; 139: 187-192. doi: 10.1016/j.ijcard.2008.10.018.
21. Ambrosio G, Weisman HF, Mannisi JA et al. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation, 1989; 80: 1846-1861. doi: 10.1161/01.CIR.80.6.1846.
22. Frangogiannis NG, Entman ML. Targeting the chemokines in myocardial inflammation. Circulation, 2004; 110: 1341-1342. doi: 10.1161/01.CIR.0000141560.18364.63.
23. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res, 2002; 53: 31-47. doi: 10.1016/S0008-6363(01)00434-5.
24. Porto I, Biasucci LM, De Maria GL et al. Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. Eur Heart J, 2012; 33: 2928-2938. doi: 10.1093/eurheartj/ehs065.
25. Aleman MM, Gardiner C, Harrison P et al. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost, 2011; 9: 2251-2261. doi: 10.1111/j.1538-7836.2011. 04488.x.
26. Rousseau M, Yan RT, Tan M et al. Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Relation between hemoglobin level and recurrent myocardial ischemia in acute coronary syndromes detected by continuous electrocardiographic monitoring. Am J Cardiol, 2010; 106: 1417-1422. doi: 10.1016/j. amjcard.2010.07.009.
27. Nikolsky E, Mehran R, Aymong ED et al. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. Am J Cardiol, 2004; 94: 1023-1027. doi: 10.1016/j. amjcard.2004.06.058.
28. Arbel Y, Milwidsky A, Finkelstein A et al. Anemia in ST-elevation myocardial infarction patients with markers of inadequate bone marrow response. Isr Med Assoc J, 2015; 17: 500-5004.